VKTX Viking Therapeutics, Inc.

Mentions (50)

• Newszacks.com·2d ago·Negative

  Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know Viking Therapeutics, Inc. (VKTX) reached $25.11 at the closing of the latest trading day, reflecting a -8.26% change compared to its last close.

  View source ↗
• Newszacks.com·4d ago·Neutral

  Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

  View source ↗
• Newsfool.com·8d ago·Negative

  Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

  View source ↗
• Newszacks.com·9d ago·Neutral

  Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.53, representing a +2.88% change from its previous close.

  View source ↗
• Newszacks.com·10d ago·Negative

  Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.73, denoting a -2.84% move from the preceding trading day.

  View source ↗
• Newszacks.com·11d ago·Negative

  VKTX Advances Obesity Program With New Oral Maintenance Study VK2735's oral maintenance study could expand Viking Therapeutics' obesity strategy by helping sustain weight loss with less frequent dosing.

  View source ↗
• Newszacks.com·12d ago·Neutral

  VKTX Down 16% in a Month: Time to Invest or Exit the Stock? Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.

  View source ↗
• Newszacks.com·17d ago·Neutral

  Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $30.51, moving 6.41% from the previous trading session.

  View source ↗
• Newszacks.com·18d ago·Neutral

  Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $32.74, signifying a +2.92% move from its prior day's close.

  View source ↗
• Newsprnewswire.com·20d ago·Negative

  …n Stock and Convertible Senior Notes Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its concurrent upsized public offerings of 9,035,714 shares of common stock, at a public offering price of $35.00 per share, and $258.75 million aggregate principal amo…

  View source ↗
• News (RSS)fool·20d ago·Negative

  Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

  View source ↗
• Newsseekingalpha.com·20d ago·Neutral

  …strong VK2735 maintenance trial results in obesity, showing robust induced weight loss and promising tolerability with less frequent dosing in the maintenance phase. VKTX demonstrated competitive or superior efficacy to Eli Lilly's tirzepatide and retatrutide across comparable time points, with tolerability expected to improve in phase 3 with less aggressive titration. The $500 million equity and convertible note offering temporarily pressured shares but was a necessary step to support advancing…

  View source ↗
• Newszacks.com·20d ago·Neutral

  Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

  View source ↗
• Newsfool.com·21d ago·Negative

  Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution The drug candidate's subcutaneous results are strong, but oral formulation data is still pending. The upcoming oral maintenance trial results are crucial to VKTX's dual-formulation strategy.

  View source ↗
• Newsdefenseworld.net·21d ago·Positive

  Top Restaurant Stocks To Research – September 26th McDonald's, Booking, Airbnb, Starbucks, Royal Caribbean Cruises, Viking, and DoorDash are the seven Restaurant stocks to watch today, according to MarketBeat's stock screener tool. Restaurant stocks are shares of publicly traded companies that operate restaurants, food-service chains, or related dining businesses. Their performance is often influenced by consumer spending, sales growth, food and labor costs,

  View source ↗
• Newsfool.com·21d ago·Negative

  3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing The company's key drug continues to demonstrate it can produce rapid weight loss in people with obesity. The maintenance dosing data support its potential to generate sustained weight loss for patients.

  View source ↗
• News (RSS)fool·23d ago·Neutral

  Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? The biotech player could eventually rival big pharma companies.

  View source ↗
• Newszacks.com·24d ago·Neutral

  Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $36.75, moving 11.76% from the previous trading session.

  View source ↗
• News (RSS)zerohedge·24d ago·Negative

  NatGas Spikes As Major West Virginia Pipeline Declares Force Majeure NatGas Spikes As Major West Virginia Pipeline Declares Force Majeure TC Energy's Columbia Gas Transmission pipeline system issued a notice requiring an "immediate pressure reduction" on Mountaineer XPress Line 100 between the Mt. Olive Compressor Station in Jackson County and the Saunders Creek Regulator Station in Cabell County, West Virginia, warning that an "expected mechanical issue" would reduce scheduled volumes. Columbia

  View source ↗
• Newsbenzinga.com·24d ago·Neutral

  Why Is Viking Therapeutics Stock Trading Down Thursday? Viking Therapeutics Inc. (NASDAQ:VKTX) shares are trading lower by at least 15% on Thursday as investors digest news of an upsized equity offering and convertible senior notes financing, while S&P 500 futures are down 0.5%.

  View source ↗
• News (RSS)seekingalpha·24d ago·Neutral

  Viking Therapeutics prices upsized $500M offering of common stock and convertible senior notes

  View source ↗
• Newsprnewswire.com·24d ago·Neutral

  …eutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent public offerings of 7,857,143 shares of common stock, at a public offering price of $35.00 per share, and $225.0 million aggregate principal amount of 2.…

  View source ↗
• News (RSS)seekingalpha·25d ago·Neutral

  Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2026 Update

  View source ↗
• News (Marketaux)gurufocus.com·25d ago·Positive

  Viking Therapeutics (VKTX) Plans $400M Capital Raise Amid Mixed Market Signals On September 23, 2026, Viking <[+216 characters]

  View source ↗
• News (RSS)fool·25d ago·Neutral

  Viking Stock Has Gained 254% Since Its IPO. Here's Whether That Run Is Anywhere Near Over. The economy may be sputtering, but the luxury travel niche is not.

  View source ↗
• Newszacks.com·25d ago·Positive

  Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $41.65, representing a +1.96% change from its previous close.

  View source ↗
• News (RSS)seekingalpha·25d ago·Positive

  Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment Optionality

  View source ↗
• Newsbenzinga.com·25d ago·Negative

  QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days Viking Therapeutics (NASDAQ:VKTX) shares are surging after the company reported positive results for its weight-loss drug candidate — the stock gained over 40% in two days.

  View source ↗
• Newsprnewswire.com·25d ago·Negative

  …g Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other conditions, $200.0 million of common stock and $200.0 million aggregate principal amount of convertible senior notes due 2032 (the …

  View source ↗
• Newsseekingalpha.com·25d ago·Neutral

  …nt Optionality Viking Therapeutics maintains a 'Strong Buy' rating, driven by positive phase 2 and maintenance data for its dual GLP-1/GIP agonist VK2735 in obesity. VKTX is advancing both injectable [SC] and oral VK2735, with phase 3 SC studies ongoing and phase 3 oral studies expected to initiate in Q4 2026. SC VK2735 demonstrated robust maintenance of weight loss—97% with every-other-week and 90% with monthly dosing—highlighting differentiation potential versus competitors.

  View source ↗
• Newszacks.com·25d ago·Negative

  VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.

  View source ↗
• News (RSS)seekingalpha·25d ago·Neutral

  Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes - Slideshow

  View source ↗
• Newsfool.com·26d ago·Neutral

  Why Viking Therapeutics Stock Skyrocketed on Tuesday Participants in a maintenance study of VK2735 maintained up to 97% of their weight loss after 12 weeks. The global obesity drug market could grow to $150 billion by 2035.

  View source ↗
• News (RSS)yahoo·26d ago·Negative

  Viking Therapeutics (VKTX) Rockets 35.7% After Weight Loss Drug Trial — What’s The Selling Point?

  View source ↗
• News (RSS)yahoo·26d ago·Neutral

  Sandisk, Lennar, Viking Therapeutics, Shopify, GameStop, and More Stocks That Explain Today’s Market

  View source ↗
• News (RSS)marketwatch·26d ago·Negative

  This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock soared.

  View source ↗
• Newsseekingalpha.com·26d ago·Positive

  Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes Transcript Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes Transcript

  View source ↗
• Newsproactiveinvestors.com·26d ago·Negative

  Viking Therapeutics shares surge over 27% on weight loss drug maintenance data Viking Therapeutics (NASDAQ:VKTX), the clinical-stage biopharmaceutical company, surged over 27% in Tuesday morning trade after reporting trial data showing its obesity drug VK2735 maintained most patients' initial weight loss with less frequent dosing. The drug, a dual agonist targeting the GLP-1 and GIP receptors involved in appetite regulation, demonstrated weight loss maintenance after patients switched to less fr…

  View source ↗
• Newsmarketbeat.com·26d ago·Neutral

  Viking Therapeutics' VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing Viking Therapeutics NASDAQ: VKTX reported top-line results from a maintenance dosing study of VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity, showing that participants retained much of their initial weight loss after transitioning from weekly treatment to every-other-week or monthly dosing schedules.

  View source ↗
• Newsreuters.com·26d ago·Negative

  Viking Therapeutics' obesity drug shows 22% weight loss in study Viking Therapeutics ​said ‌on Tuesday its ​experimental ​GLP-1 obesity ⁠drug ​helped patients ​lose 22% of ​their ​body weight after ‌33 ⁠weeks of weekly ​treatment ​in ⁠a maintenance ​study.

  View source ↗
• Newszacks.com·32d ago·Neutral

  Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.52, representing a -1.44% change from its previous close.

  View source ↗
• Newsbenzinga.com·33d ago·Positive

  What's Going On With the Dip in Viking Therapeutics Stock? Viking Therapeutics Inc. (NASDAQ:VKTX) shares are dropping Tuesday amid a broader risk-off session, even though the stock's longer-term uptrend and its sector's strength both remain intact.

  View source ↗
• Newsseekingalpha.com·34d ago·Positive

  Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  View source ↗
• Newszacks.com·37d ago·Positive

  Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

  View source ↗
• Newszacks.com·38d ago·Neutral

  Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.

  View source ↗
• Newszacks.com·39d ago·Neutral

  Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know Viking Therapeutics, Inc. (VKTX) closed at $32.7 in the latest trading session, marking a -2.91% move from the prior day.

  View source ↗
• Newsfool.com·43d ago·Negative

  Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. Viking Therapeutics has significant upside potential based on Wall Street targets. VK2735's dual-formulation strategy could differentiate it in a crowded obesity drug market, but it faces major risks, including strong competition and safety concerns with the oral formulation.

  View source ↗
• Newszacks.com·45d ago·Positive

  Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know Viking Therapeutics, Inc. (VKTX) closed at $33.98 in the latest trading session, marking a +1.43% move from the prior day.

  View source ↗
• Newsprnewswire.com·46d ago·Neutral

  Viking Therapeutics to Participate at Upcoming Investor Conferences SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum in September.

  View source ↗
• Newsfool.com·49d ago·Negative

  Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.

  View source ↗